ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RUA Rua Life Sciences Plc

11.375
0.25 (2.25%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Rua Life Sciences Plc LSE:RUA London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 2.25% 11.375 10.75 12.00 11.375 11.125 11.13 90,931 08:24:24
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Plastics,resins,elastomers 2.18M -2M -0.0323 -3.52 7.06M
Rua Life Sciences Plc is listed in the Plastics,resins,elastomers sector of the London Stock Exchange with ticker RUA. The last closing price for Rua Life Sciences was 11.13p. Over the last year, Rua Life Sciences shares have traded in a share price range of 8.65p to 58.50p.

Rua Life Sciences currently has 62,060,272 shares in issue. The market capitalisation of Rua Life Sciences is £7.06 million. Rua Life Sciences has a price to earnings ratio (PE ratio) of -3.52.

Rua Life Sciences Share Discussion Threads

Showing 3476 to 3497 of 3625 messages
Chat Pages: 145  144  143  142  141  140  139  138  137  136  135  134  Older
DateSubjectAuthorDiscuss
05/4/2024
09:25
I think that is reading too much into the wording. They are partners as they have an MTA in place
harrogate
05/4/2024
09:20
Just one decent commercial deal and the market cap is worth a lot more than current £6M that's for sure.
parob
05/4/2024
09:16
No mention of the Stent test.
controlledmadness
05/4/2024
09:16
I was intrigued by this wording about the MTA:

“……;….is currently being tested by this partner”.

Are they already a partner? A party to a testing agreement maybe, but a partner seems to imply a stronger relationship.

bones
05/4/2024
09:11
This being key:"the Company is pleased to announce that it has succeeded in securing the initial development stages of a significant contract with a global enterprise."Looking forward to hearing further updates on this.
parob
05/4/2024
09:07
https://www.londonstockexchange.com/news-article/APH/full-year-trading-update/16307097
blackhorse23
05/4/2024
08:59
Very good update imo. Plenty of cash/time to get sone commercial deals over the line. Speculation alone could drive this higher. Business Update RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), today provides an update on trading for the financial year ending 31 March 2024 and developments since the successful fundraise in December 2023.TradingThe first half of the financial year was impacted by operational issues, resulting in the delayed shipment of products from the Contract Manufacturing business. As anticipated, the revenue shortfall experienced during H1 has been fully compensated by a strong H2 performance. As a result, the Company expects to report, subject to audit, FY24 revenue of £2.2 million, which is in line with market expectations. The Company is pleased to announce that the recovery in revenues has not been at the cost of gross margins, and it is anticipated that reported margins will exceed expectations. The Group has focussed on cost control throughout the year. These rigorous measures are expected to result in operating costs of £3.4 million, approximately £0.2 million below market expectations for the year.Cash PositionStrong cost management, together with the anticipated recovery in trading during the second half, means the Company remains financially resilient, with a strong balance sheet and a cash position of approximately £4.0m. Despite challenging trading conditions, these achievements underscore the Group's resilience and adeptness in financial and operational management.Business DevelopmentSignificant efforts have been focussed on business development activities as part of the Group's strategy to reach profitability in the short term. It has been the strategy to seek to grow the scale of contract manufacturing, and the Company is pleased to announce that it has succeeded in securing the initial development stages of a significant contract with a global enterprise. This contract represents a major milestone on the route to doubling revenues for the contract manufacturing division once fully operational. Initial development work under this contract has commenced, with an initial purchase order valued at £100,000 already received.Additionally, as announced on 20 December 2023, the Company has successfully entered into a Material Transfer Agreement (MTA) with a global Heart Valve company. The Group's composite material has been delivered and is currently being tested by this partner. The non-calcific nature of Elast-Eon, together with the tear resistance of the novel composite (up to two times improvement over current materials), positions RUA as a leader in developing next-generation alternative leaflet material resistant to Structural Valve Degeneration (SVD). The Company is confident that these results will be of significant interest to other prospective partners and is actively exploring additional potential partnerships.Bill Brown, Chairman of RUA Life Sciences, stated: "Trading results for FY24 represent a meaningful step in delivering on the Group's strategy outlined in November, and the efforts to focus the business on growth are showing promise."Commenting on the Contract Manufacturing success, Bill added:"Securing this contract underscores RUA's expertise in implantable fabrics and moves us closer to profitability. It is our first major contract since the acquisition of RUA Medical Devices in 2020 and supports our belief that there are significant market opportunities in this area."Bill further elaborated on the heart valve composite by stating:"Our material has exceeded expectations, demonstrating remarkable durability and energy efficiency compared to market-leading valves. We are actively seeking partnerships to leverage these compelling results. RUA believes that these outstanding results in preclinical and bench studies are a result of the unique combination of RUA's expertise in medical fabrics and the biostability of Elast-Eon"
parob
04/4/2024
22:15
15/16p tmoz
letsbuy1
04/4/2024
21:27
Definite pump and dump imo. Lse site is full of it.
nik7907
04/4/2024
19:18
Always a joy to get new posters
harrogate
04/4/2024
19:04
Placing hahahha are you some kind of. D. I C K. Stop lying and putting S. H. I. T on here. There fully funded for. Years you. C. U. N. T after the massive raise at Xmas
What a. P. R. I. C K

letsbuy1
04/4/2024
18:56
Require placing in here & no money in bank. Switched to APH [LSE] , an excellent profitable health care company
blackhorse23
04/4/2024
18:37
Got another £30000 to fill in the morning
letsbuy1
04/4/2024
18:00
Bought £40000 worth in the end
letsbuy1
04/4/2024
17:52
Ah I see, could be a factor, true.
bones
04/4/2024
17:40
I was suggesting today's action is because of the 5th April deadline for all, not you personally!
cocker
04/4/2024
16:37
I’ve enough already, ta.
bones
04/4/2024
16:32
Is it not the last day to top up your share isa's Bones
cocker
04/4/2024
15:48
Bones,quite possibly but if you don't mind , I'll just wave you off this time.
cocker
04/4/2024
15:38
P&D incoming!!!!!!!!
chesty1
04/4/2024
15:29
& if anyone wondered why the placing was done at such a discount then there we have it with letsbuy1, to entice the next round of penny share punters.
cocker
04/4/2024
15:16
Impossible to buy. Float is empty. This will absolutely explode soon
letsbuy1
Chat Pages: 145  144  143  142  141  140  139  138  137  136  135  134  Older

Your Recent History

Delayed Upgrade Clock